- Home
- BZAI vs TLSA Comparison
BZAI vs TLSA Comparison
Compare BZAI & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZAI
- TLSA
- Stock Information
- Founded
- BZAI 2010
- TLSA 2013
- Country
- BZAI United States
- TLSA United Kingdom
- Employees
- BZAI N/A
- TLSA N/A
- Industry
- BZAI
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- BZAI
- TLSA Health Care
- Exchange
- BZAI Nasdaq
- TLSA Nasdaq
- Market Cap
- BZAI 206.4M
- TLSA 187.0M
- IPO Year
- BZAI N/A
- TLSA 2000
- Fundamental
- Price
- BZAI $2.80
- TLSA $1.44
- Analyst Decision
- BZAI Buy
- TLSA
- Analyst Count
- BZAI 2
- TLSA 0
- Target Price
- BZAI $6.50
- TLSA N/A
- AVG Volume (30 Days)
- BZAI 466.7K
- TLSA 193.5K
- Earning Date
- BZAI 08-15-2025
- TLSA 07-22-2025
- Dividend Yield
- BZAI N/A
- TLSA N/A
- EPS Growth
- BZAI N/A
- TLSA N/A
- EPS
- BZAI N/A
- TLSA N/A
- Revenue
- BZAI $2,012,000.00
- TLSA N/A
- Revenue This Year
- BZAI $1,504.31
- TLSA N/A
- Revenue Next Year
- BZAI $372.18
- TLSA N/A
- P/E Ratio
- BZAI N/A
- TLSA N/A
- Revenue Growth
- BZAI N/A
- TLSA N/A
- 52 Week Low
- BZAI $1.70
- TLSA $0.63
- 52 Week High
- BZAI $29.61
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- BZAI N/A
- TLSA 46.42
- Support Level
- BZAI N/A
- TLSA $1.43
- Resistance Level
- BZAI N/A
- TLSA $1.81
- Average True Range (ATR)
- BZAI 0.00
- TLSA 0.09
- MACD
- BZAI 0.00
- TLSA -0.02
- Stochastic Oscillator
- BZAI 0.00
- TLSA 10.53
About BZAI Blaize Holdings Inc. Common Stock
Blaize Holdings Inc provides customized, programmable processor architecture suite, artificial intelligence (AI)-enabled edge computing solutions. The company is a semiconductor and software technology company dedicated to revolutionizing the world of AI.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.